Randomized Clinical Trial to Evaluate the Efficacy and Safety of Product CM9241GRU in Relieving Nasal Symptoms in Perennial Allergic Rhinitis
Latest Information Update: 06 Sep 2024
Price :
$35 *
At a glance
- Drugs CM 9241 GRU (Primary)
- Indications Perennial allergic rhinitis
- Focus Therapeutic Use
- Acronyms RESPIRE
- Sponsors Ache Laboratories
- 06 Sep 2024 New trial record